• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Erleada (apalutamide)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Erleada (apalutamide)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Erleada (apalutamide) is an androgen receptor inhibitor.

    Erleada is specifically indicated for the treatment of non-metastatic, castration-resistant prostate cancer. Erleada was approved in September of 2019 for use in the treatment of metastatic prostate cancer. 

    Erleada is supplied as a tablet for oral administration. The recommended dose of Erleada is 240 mg (four 60 mg tablets) administered orally once daily. Swallow the tablets whole. Erleada can be taken with or without food. Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.

    If a patient experiences a greater than or equal to Grade 3 toxicity or an intolerable side effect, hold dosing until symptoms improve to less than or equal to Grade 1 or original grade, then resume at the same dose or a reduced dose (180 mg or 120 mg), if warranted. 

    Clinical Results

    FDA Approval

    The FDA approval of Erleada for non-metastatic prostate cancer was based on SPARTAN, a Phase III, randomized, double-blind, placebo-controlled, multi-center study conducted in 1,207 subjects with non-metastatic castration-resistant prostate cancer. The subjects were randomized 2:1 to receive either Erleada orally at a dose of 240 mg once daily (n=806), or placebo once daily (n=401). All subjects received a concomitant gonadotropin-releasing hormone (GnRH) analog or had a bilateral orchiectomy. Erleada decreased the risk of distant metastasis or death by 72 percent compared to placebo (P<0.0001). The median MFS was 40.51 months for Erleada compared to 16.20 months for placebo, prolonging MFS by more than two years (difference of 24.31 months). The major efficacy outcome was supported by statistically significant improvements for the following secondary endpoints: time to metastasis (TTM), progression-free survival (PFS) and time to symptomatic progression. The median TTM was 40.51 months for Erleada compared to 16.59 months for placebo (P<0.0001) and the median PFS was 40.51 months compared to 14.72 months for placebo (P<0.0001).

    The FDA approval of Erleada for metastatic prostate cancer was based on the phase III TITAN study that included 1,052 patients in 23 countries across 260 sites in North America, Latin America, South America, Europe, and Asia Pacific. The patients with mCSPC were randomized 1:1 and received either Erleada (240 mg) plus ADT or placebo plus ADT. Data showed that Erleada plus ADT significantly extended overall survival (OS) compared to placebo plus ADT, obtaining a 33% decrease in the risk of death. It also significant improved radiographic progression-free survival (rPFS) compared to the control group with a 52% lower risk of radiographic progression or death.

    Side Effects

    Adverse effects associated with the use of Erleada may include, but are not limited to, the following:

    • fatigue
    • hypertension
    • rash
    • diarrhea
    • nausea
    • weight decreased
    • arthralgia
    • fall
    • hot flush
    • decreased appetite
    • fracture
    • peripheral edema

     

    Mechanism of Action

    Erleada (apalutamide) is an androgen receptor inhibitor that binds directly to the ligand-binding domain of the AR. Apalutamide inhibits AR nuclear translocation, inhibits DNA binding, and impedes AR-mediated transcription. 

    Additional Information

    For additional information regarding Erleada or non-metastatic castration-resistant prostate cancer, please visit https://www.erleada.com/

    Approval Date: 2018-02-01
    Company Name: Janssen Oncology
    Back to Listings

    Upcoming Events

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Qualification-360x240.png

      Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

    • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

    • MachineLearning-360x240.png

      Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

    • VirtualTraining-360x240.png

      Virtual Training Evolves into More In-Depth Learning, Improved Communications

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing